Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis.

Abstract

STUDY OBJECTIVE:

To compare the performance of polyclonal fluorescence polarization immunoassay (pFPIA) with that of enzyme-multiplied immunoassay technique (EMIT) in patients receiving vancomycin and hemodialysis.

SETTING:

Outpatient hemodialysis center.

PATIENTS:

Seven subjects with end-stage renal disease treated with hemodialysis 3 times/week with a cellulose triacetate hemodialyzer.

INTERVENTION:

Subjects received vancomycin 1000 mg intradialytically during the first study session and 750 mg every other hemodialysis session thereafter for 4 weeks.

MEASUREMENTS AND MAIN RESULTS:

Blood samples were obtained throughout the study, and vancomycin serum concentrations were determined by pFPIA and EMIT. The mean +/- SD difference (estimate of bias) between assays was -1.10 +/- 1.35 mg/L. The limits of agreement (mean difference +/- 1.96 x SD) between them were -3.80-1.60 mg/L.

CONCLUSION:

Our data suggest that the manufacturer's changes in the vancomycin pFPIA eliminated overestimation of drug concentrations in patients undergoing high-permeability hemodialysis.

• Authors: J R Kingery, K M Sowinski, M A Kraus, J E Klaunig, B A Mueller
• Journal: Pharmacotherapy (Pharmacotherapy) Vol. 20 Issue 6 Pg. 653-6 (Jun 2000) ISSN: 0277-0008 [Print] United States
• PMID: 10853620 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Vancomycin

Topics

• Anti-Bacterial Agents (blood)
• Enzyme Multiplied Immunoassay Technique
• Fluorescence Polarization
• Humans
• Immunoassay
• Vancomycin (blood)